CYTX - Cytori Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3202
-0.0052 (-1.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.3254
Open0.3263
Bid0.0000 x 7000
Ask0.0000 x 1600
Day's Range0.3200 - 0.3382
52 Week Range0.2900 - 5.4000
Volume98,887
Avg. Volume583,974
Market Cap4.227M
Beta (3Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-3.3830
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Trade prices are not sourced from all markets
  • Benzinga7 days ago

    Shares Of Penny Stock Cytori Rise On Japanese Device Approval

    Cytori announced it has received approval for its Cellution Cell Therapy System consumable bundle in Japan as a Class III medical device. The Cellution Cell Therapy System is a medical device designed to automate processing of adipose tissue to obtain regenerative cells suitable for treating thermal and radioactive burn wounds.

  • GlobeNewswire7 days ago

    Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product

    Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced that the Company has received approval for the Celution Cell Therapy System consumable bundle in Japan as a Class III medical device. The Class III designation will allow Cytori to expand its current commercial efforts in Japan and provides a clear framework for future expanded regulatory claims and reimbursement under the November 2014 PMD Act. Furthermore, Cytori announced today that the Company has successfully outsourced an important assembly portion of the production process for its Celution Cell Therapy consumables from San Diego, CA to Viant Medical in San Antonio, Texas.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of CYTX earnings conference call or presentation 14-Nov-18 10:30pm GMT

    Q3 2018 Cytori Therapeutics Inc Earnings Call

  • Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates
    Zacks25 days ago

    Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates

    Cytori (CYTX) delivered earnings and revenue surprises of -246.15% and -59.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press25 days ago

    Cytori: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 55 cents. Losses, adjusted for one-time items, came to 45 cents per share. The developer of cell therapies posted revenue of $1.3 ...

  • GlobeNewswirelast month

    Cytori to Webcast Third Quarter Financial Results on November 14

    SAN DIEGO, Nov. 09, 2018 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday,.

  • GlobeNewswirelast month

    Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone

    Cytori Therapeutics, Inc. (CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies, LLC (Bimini). The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divestiture of the Puregraft® product line. In 2013, Cytori entered into a Sale and Exclusive License/Supply Agreement with Bimini, pursuant to which Cytori sold to Bimini selected assets relating to Cytori’s Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring.

  • Simply Wall St.2 months ago

    Cytori Therapeutics Inc (NASDAQ:CYTX) Is Expected To Breakeven

    Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical Read More...

  • Cytori's Chemotherapy Candidate Gets Orphan Drug Status
    Zacks3 months ago

    Cytori's Chemotherapy Candidate Gets Orphan Drug Status

    Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.

  • GlobeNewswire3 months ago

    Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation

    The FDA’s Orphan Drug Designation Program provides orphan status to drugs, such as ATI-1123, which are intended for the safe and effective treatment of rare diseases/disorders that affect fewer than 200,000 people in the U.S.  Sponsors of a drug receiving orphan designation qualify for various incentives including tax credits for clinical testing, 7 years of marketing exclusivity following FDA approval, and a waiver of prescription drug user fees. Small cell lung cancer (SCLC), which accounts for approximately 15% of bronchogenic carcinomas with 33,375 new cases and 23,380 deaths estimated for 2017, has been identified by Cytori as a compelling target for ATI-1123.  While SCLC is responsive to chemotherapy and radiation therapy, cure occurs only in ~20% of patients, generally restricted to those with limited stage disease.  The remaining 80% of patients, including all patients with extensive disease, relapse within months of completing their initial therapy.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CYTX earnings conference call or presentation 14-Aug-18 9:30pm GMT

    Q2 2018 Cytori Therapeutics Inc Earnings Call

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Medtronic and Cytori Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Medtronic shares hit a brand new high after announcing impressive first quarter results. Shares of Cytori Therapeutics also soared in Tuesday’s session despite ...

  • Benzinga4 months ago

    The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

    Here's a roundup of top developments in the biotech space over the last 24 hours.  Scaling the Peaks (Stocks hitting 52-week highs on Aug. 15) Inspire Medical Systems Inc (NYSE: INSP ) Merck & Co., Inc. ...

  • Benzinga4 months ago

    The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 14) DexCom, Inc. (NASDAQ: DXCM ) Masimo Corporation (NASDAQ: MASI ...

  • Associated Press4 months ago

    Cytori: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 59 cents per share. The developer of cell therapies posted revenue of $1.6 million in the period. In the final minutes of trading on Tuesday, the company's ...

  • Benzinga4 months ago

    The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 13) Iradimed Corp (NASDAQ: IRMD ) SurModics, Inc. (NASDAQ: SRDX ...